MoonLake Immunotherapeutics's total assets for Q3 2024 were $518.21M, a decrease of -4.89% from the previous quarter. MLTX total liabilities were $22.71M for the fiscal quarter, a 52.98% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.